EGFR Neoantigen Peptide Vaccine Combined with Tislelizumab and Chemotherapy for Advanced NSCLC Resistant to EGFR-TKI Therapy

被引：0
|
作者：
Wang, L. [1 ]
Su, S. [2 ,3 ]
Lv, X. [2 ,3 ]
Liu, Y. [2 ,3 ]
Chen, F. [2 ,3 ]
Shao, J. [2 ,3 ]
Liu, B. [2 ,3 ]
机构：
[1] Nanjing Drum Tower Hosp, Ctr Comprehens Canc, Nanjing, Peoples R China
[2] Nanjing Univ, Sch Med, Nanjing Drum Tower Hosp, Ctr Comprehens Canc, Nanjing, Peoples R China
[3] Nanjing Univ, Nanjing Drum Tower Hosp, Affiliated Hosp, Med Sch,Clin Canc Inst, Nanjing, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期
关键词：
Neoantigen vaccine; EGFR mutation; NSCLC;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P4.11D.05
引用
收藏
页码：S391 / S391
页数：1
相关论文
共 50 条
  • [1] EGFR-TKI Combined with Pemetrexed versus EGFR-TKI Monotherapy in Advanced EGFR-Mutated NSCLC: A Prospective, Randomized, Exploratory Study
    Gu, Weiguang
    Zhang, Hua
    Lu, Yiyu
    Li, Minjing
    Yang, Shuang
    Liang, Jianmiao
    Ye, Zhijian
    Li, Zhihua
    He, Minhong
    Shi, Xiaoliang
    Wang, Fei
    You, Dong
    Gu, Weiquan
    Feng, Weineng
    CANCER RESEARCH AND TREATMENT, 2023, 55 (03): : 841 - 850
  • [2] EGFR-TKI plus /- Antiangiogenics for EGFR-mutated Advanced NSCLC
    da Silva, L. L.
    Matsas, S.
    Aguiar, P., Jr.
    Taveira, G. M. T.
    Barcelos, I. F.
    Lopes, G. L., Jr.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S416 - S417
  • [3] Comparing EGFR-TKI with EGFR-TKI plus Chemotherapy as 1st Line Treatment in Advanced NSCLC Patients with Both Mutated EGFR and Bim Polymorphism
    He, Y.
    Zhao, C.
    Li, X.
    Ren, S.
    Jiang, T.
    Zhang, J.
    Su, C.
    Chen, X.
    Cai, W.
    Gao, G.
    Li, W.
    Wu, F.
    Li, J.
    Zhao, J.
    Zhou, F.
    Hu, Q.
    Hirsch, F. R.
    Zhou, C.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1970 - S1970
  • [4] The efficacy of chemotherapy in the advanced NSCLC patients who failed with the treatment of EGFR-TKI
    Zhou, S.
    Ren, S.
    Zhang, L.
    Sun, H.
    Zhou, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [5] EGFR fusion mutation combined with EGFR amplification responds to EGFR-TKI therapy
    Wang, Zhulin
    Huang, Chunyao
    Fan, Wenbo
    Sun, Shaowu
    Li, Kaiyuan
    Liu, Xu
    Pu, Jiangtao
    Zhang, Guoqing
    Li, Xiangnan
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [6] The Third Generation EGFR Inhibitor (EGFR-TKI) HS-10296 in Advanced NSCLC Patients with Resistance to First Generation EGFR-TKI
    Lu, S.
    Wang, Q.
    Zhang, G.
    Dong, X.
    Yang, C.
    Song, Y.
    Chang, G.
    Lu, Y.
    Pan, H.
    Chiu, C.
    Wang, Z.
    Feng, J.
    Zhou, J.
    Xu, X.
    Guo, R.
    Chen, J.
    Yang, H.
    Chen, Y.
    Yu, Z.
    Shiah, H.
    Wang, C.
    Yang, N.
    Fang, J.
    Wang, P.
    Wang, K.
    Hu, Y.
    He, J.
    Wang, Z.
    Shi, J.
    Chen, S.
    Cheng, Y.
    Su, W.
    Hsia, T.
    Cui, J.
    Sun, Y.
    Yang, C.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S208 - S209
  • [7] EGFR-TKI FOR EGFR MUTATED NSCLC: NEW EVIDENCE
    Okamoto, I.
    ANNALS OF ONCOLOGY, 2010, 21 : 40 - 40
  • [8] Comparison of EGFR-TKI and chemotherapy in the first-line treatment of advanced EGFR mutation-positive NSCLC
    Fiala, O.
    Pesek, M.
    Finek, J.
    Benesova, L.
    Bortlicek, Z.
    Minarik, M.
    NEOPLASMA, 2013, 60 (04) : 425 - 431
  • [9] Pemetrexed combined with cisplatin for patients with EGFR-TKI resistant advanced lung cancer
    Zhou, Zunyan
    Yang, Jiyuan
    Li, Hongtao
    Luo, Fei
    Shao, Chengze
    Wang, Qian
    Du, Wei
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2019, 12 (07): : 8678 - 8685
  • [10] An evaluation of phosphorylated EGFR expression in predicting outcome of EGFR-TKI therapy for the advanced NSCLC patients with EGFR wild type.
    Wang, F.
    Wang, J.
    Bai, H.
    Zhao, J.
    Wang, Z.
    Zhuo, M.
    An, T.
    Duan, J.
    Yang, L.
    Wu, M.
    Wang, Y.
    Wang, S.
    Liu, X.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345